Cheiron Raises $8M Seed to Build the Operating System for Drug Programs
July 23, 2026
2 minute read
We're announcing Cheiron's $8M seed round, led by Menlo Ventures, to build the first AI-native operating system for drug programs.
Drug development runs on thousands of interconnected pieces of evidence—experiments, clinical results, regulatory filings, competitive intelligence, scientific literature, and institutional memory. Despite billions of dollars invested in every program, the program itself has never existed as software. The knowledge that determines whether a therapy succeeds is scattered across papers, trials, filings, and people's heads, and teams burn enormous time reconstructing context before they can make a single decision. The information was never missing. The system for representing it was.
Today, we're announcing an $8M seed round led by Menlo Ventures with the backing and strategic support of industry veterans including Moderna co-founder and MIT Institute Professor Robert Langer; former Pfizer Chief Medical Officer Freda Lewis-Hall; Chai Discovery co-founder and CEO Josh Meier; former Starbucks CEO Laxman Narasimhan among others.
About Cheiron
Cheiron models the live state of a drug program as a single connected system—the claims, evidence, assumptions, risks, decisions, and commitments that determine whether a therapy advances.
At the center of the platform is our proprietary Life Sciences Knowledge Graph (LKG), connecting biomedical, clinical, regulatory, patent, and commercial knowledge into one model built for the inferences drug developers make every day: cross-referencing a trial design against regulatory precedent, surfacing contradictions between a competitor's data and their patents, or stress-testing a hypothesis against the full body of available evidence.
We're just getting started
This round accelerates development of the Knowledge Graph, expands Cheiron across clinical, regulatory, and strategic workflows, and grows our engineering, product, and life sciences teams. We're also welcoming a group of scientific and operating advisors who've built and led drug programs at the highest levels of the industry.
We're building toward a future where the people responsible for a drug program spend their time on judgment, not archaeology. If that future excites you, we'd love to hear from you.
